Evidence map›Paper›PMID 37179057›Full record

ArticleAnalytica chimica acta2023

CRISPR gel: A one-pot biosensing platform for rapid and sensitive detection of HIV viral RNA.

Naoki Uno, Ziyue Li, Lori Avery, Maroun M Sfeir, Changchun Liu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Analytica chimica acta, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Rapid and Simple Detection ofPathogens (Basel, Switzerland) · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Expanding the CRISPR/Cas toolkit: applications in proteomics and theranostics.Frontiers in bioengineering and biotechnology · 2025
    Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. HIV infection detection using CRISPR/Cas systems: Present and future prospects.Computational and structural biotechnology journal · 2023
    Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Naoki UnoDepartment of Biomedical Engineering, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA.
Ziyue LiDepartment of Biomedical Engineering, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA; Department of Biomedical Engineering, University of Connecticut, 260 Glenbrook Road, Storrs, CT, 06029, USA.
Lori AveryDepartment of Pathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, CT, 06030, USA.
Maroun M SfeirDepartment of Pathology and Laboratory Medicine, University of Connecticut Health Center, Farmington, CT, 06030, USA.
Changchun LiuDepartment of Biomedical Engineering, University of Connecticut Health Center, 263 Farmington Avenue, Farmington, CT, 06030, USA. Electronic address: chaliu@uchc.edu.
UConn Health · USUniversity of Connecticut · US

Funding

Asymmetric CRISPR Approach for Nucleic Acid QuantificationR01EB023607 · NIBIB · UNIVERSITY OF PENNSYLVANIA · PI Changchun Liu · 2017 to 2026
$2.4M
Self-Powered Sample Concentrating and CRISPR-based Biosensing for Moile HIV-1 RNA DetectionR61AI154642 · NIAID · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · PI LIU, CHANGCHUN · 2020 to 2022
$1.4M
NIAID NIH HHS R61 AI154642NIBIB NIH HHS R01 EB023607
6 · The paper itself

Abstract

CRISPR technology has recently emerged as a powerful biosensing tool for sensitive and specific nucleic acid detection when coupled with isothermal amplification (e.g., recombinase polymerase amplification (RPA)). However, it remains a challenge to incorporate isothermal amplification into CRISPR detection in a one-pot system due to their poor compatibility. Here, we developed a simple CRISPR gel biosensing platform for human immunodeficiency virus (HIV) RNA detection by combining reverse transcription-recombinase polymerase amplification (RT-RPA) reaction solution with a CRISPR gel. In our CRISPR gel biosensing platform, CRISPR-Cas12a enzymes are embedded into the agarose gel, providing a spatially separated but connected reaction interface with the RT-RPA reaction solution. During isothermal incubation, the RT-RPA amplification occurs initially on the CRISPR gel. When RPA products are sufficiently amplified and reach the CRISPR gel, the CRISPR reaction occurs in the whole tube. With the CRISPR gel biosensing platform, we successfully detected down to 30 copies of HIV RNA per test within 30 min. Furthermore, we validated its clinical utility by detecting HIV clinical plasma samples, achieving superior performance compared with the real-time RT-PCR method. Thus, our one-pot CRISPR gel biosensing platform demonstrates great potential for rapid and sensitive molecular detection of HIV and other pathogens at the point of care.

Indexed as

HIV InfectionsReverse TranscriptionHumansNucleic Acid Amplification TechniquesRecombinasesRNA, ViralSensitivity and SpecificityRecombinasesRNA, ViralAgarose gelCRISPR-Cas12aHuman immunodeficiency virusPoint-of-care diagnosticsRecombinase polymerase amplification

Identifiers

PMID37179057
PMCPMC10187225
OpenAlexW4366831588

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.